The benefit of combining EBRT with [177Lu]Lu-PSMA-617 for prostate cancer is potentially much larger when compared to these prior efforts because of multiple factors: first, The tumour-background ratio of PSMA-ligands is of the same magnitude as octreotate, and higher than phenylalanine. This evidence concerns the gene FOLH1 and neoplasm.